Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study

Blood Adv (2021) 5 (19): 3862–3872.

https://doi.org/10.1182/bloodadvances.2021004778

Published: 2021

Includes: Supplemental data

Journal Articles

HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis

Juan Pablo Alderuccio, Adam J. Olszewski, Andrew M. Evens, Graham P. Collins, Alexey V. Danilov, Mark Bower, Deepa Jagadeesh, Catherine Zhu, Amy Sperling, Seo-Hyun Kim, Ryan Vaca, Catherine Wei, Suchitra Sundaram, Nishitha Reddy, Alessia Dalla Pria, Christopher D’Angelo, Umar Farooq, David A. Bond, Stephanie Berg, Michael C. Churnetski, Amandeep Godara, Nadia Khan, Yun Kyong Choi, Shireen Kassam, Maryam Yazdy, Emma Rabinovich, Frank A. Post, Gaurav Varma, Reem Karmali, Madelyn Burkart, Peter Martin, Albert Ren, Ayushi Chauhan, Catherine Diefenbach, Allandria Straker-Edwards, Andreas Klein, Kristie A. Blum, Kirsten Marie Boughan, Agrima Mian, Bradley M. Haverkos, Victor M. Orellana-Noia, Vaishalee P. Kenkre, Adam Zayac, Seth M. Maliske, Narendranath Epperla, Paolo Caimi, Scott E. Smith, Manali Kamdar, Parameswaran Venugopal, Tatyana A. Feldman, Daniel Rector, Stephen D. Smith, Andrzej Stadnik, Craig A. Portell, Yong Lin, Seema Naik, Silvia Montoto, Izidore S. Lossos, Kate Cwynarski

Blood Adv (2021) 5 (14): 2852–2862.

https://doi.org/10.1182/bloodadvances.2021004458

Published: 2021

Includes: Supplemental data

Journal Articles

Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review

Edward J. Bataillard, Chan Yoon Cheah, Matthew J. Maurer, Arushi Khurana, Toby A. Eyre, Tarec Christoffer El-Galaly

Blood Adv (2021) 5 (9): 2426–2437.

https://doi.org/10.1182/bloodadvances.2021004665

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent–based analysis

Hyehyun Jeong, Hyungwoo Cho, Hyeyeong Kim, Heejung Chae, Jung-Bok Lee, Kyoungmin Lee, Shin Kim, Sang-wook Lee, Jin-Sook Ryu, Kyung Won Kim, Eun Jin Chae, Jooryung Huh, Chan-Sik Park, Dok Hyun Yoon, Cheolwon Suh

Blood Adv (2021) 5 (8): 2142–2152.

https://doi.org/10.1182/bloodadvances.2020003947

Published: 2021

Includes: Supplemental data

Journal Articles

Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines

Alden A. Moccia, Kimberly Schaff, Ciara Freeman, Paul J. Hoskins, Richard J. Klasa, Kerry J. Savage, Tamara N. Shenkier, Randy D. Gascoyne, Joseph M. Connors, Laurie H. Sehn

Blood Adv (2021) 5 (5): 1483–1489.

https://doi.org/10.1182/bloodadvances.2020002982

Published: 2021

Includes: Supplemental data

Journal Articles

Primary human herpesvirus 8–negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis

Daisuke Kaji, Yasunori Ota, Yasuharu Sato, Koji Nagafuji, Yasunori Ueda, Masataka Okamoto, Yasushi Terasaki, Naoko Tsuyama, Kosei Matsue, Tomohiro Kinoshita, Go Yamamoto, Shuichi Taniguchi, Shigeru Chiba, Koichi Ohshima, Koji Izutsu

Blood Adv (2020) 4 (18): 4442–4450.

https://doi.org/10.1182/bloodadvances.2020002293

Published: 2020

Includes: Supplemental data

Journal Articles

Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa

Nmazuo W. Ozuah, Joseph Lubega, Carl E. Allen, Nader Kim El-Mallawany

Blood Adv (2020) 4 (16): 4007–4019.

https://doi.org/10.1182/bloodadvances.2020002178

Published: 2020

Journal Articles

In childhood mature B-NHL with CNS disease, patients with blasts in cerebrospinal fluid are at higher risk of failure

Mathieu Simonin, Anne Auperin, Yves Bertrand, Nathalie Aladjidi, André Baruchel, Audrey Contet, Carole Coze, Virginie Gandemer, Stephanie Haouy, Thierry Leblanc, Guy Leverger, Jean Michon, Catherine Patte, Veronique Minard-Colin

Blood Adv (2020) 4 (15): 3621–3625.

https://doi.org/10.1182/bloodadvances.2019001398

Published: 2020

Journal Articles

Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma

Diego Villa, Laurie H. Sehn, Kerry J. Savage, Cynthia L. Toze, Kevin Song, Wendie D. den Brok, Ciara L. Freeman, David W. Scott, Alina S. Gerrie

Blood Adv (2020) 4 (15): 3486–3494.

https://doi.org/10.1182/bloodadvances.2020002068

Published: 2020

Includes: Supplemental data

Journal Articles

Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant

Seongseok Yun, Onyee Chan, Daniel Kerr, Nicole D. Vincelette, Afshan Idrees, Qianxing Mo, Kendra Sweet, Jeffrey E. Lancet, Mohamed A. Kharfan-Dabaja, Ling Zhang, Lubomir Sokol

Blood Adv (2020) 4 (14): 3435–3442.

https://doi.org/10.1182/bloodadvances.2020001875

Published: 2020

Includes: Supplemental data

Journal Articles

Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma

Blood Adv (2020) 4 (14): 3382–3390.

https://doi.org/10.1182/bloodadvances.2020001551

Published: 2020

Includes: Supplemental data

Journal Articles

Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification

Ichiro Yonese, Chizuko Sakashita, Ken-Ichi Imadome, Tohru Kobayashi, Masahide Yamamoto, Akihisa Sawada, Yoshinori Ito, Noriko Fukuhara, Asao Hirose, Yusuke Takeda, Masanori Makita, Tomoyuki Endo, Shun-ichi Kimura, Masataka Ishimura, Osamu Miura, Shouichi Ohga, Hiroshi Kimura, Shigeyoshi Fujiwara, Ayako Arai

Blood Adv (2020) 4 (13): 2918–2926.

https://doi.org/10.1182/bloodadvances.2020001451

Published: 2020

Includes: Supplemental data

Journal Articles

Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma

Blood Adv (2020) 4 (13): 2886–2898.

https://doi.org/10.1182/bloodadvances.2020001696

Published: 2020

Includes: Supplemental data

Journal Articles

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Blood Adv (2020) 4 (9): 1906–1915.

https://doi.org/10.1182/bloodadvances.2020001518

Published: 2020

Includes: Supplemental data

Journal Articles

SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model

Luca Ceriani, Giuseppe Gritti, Luciano Cascione, Maria Cristina Pirosa, Angela Polino, Teresa Ruberto, Anastasios Stathis, Andrea Bruno, Alden A. Moccia, Luca Giovanella, Stefanie Hayoz, Sämi Schär, Stefan Dirnhofer, Alessandro Rambaldi, Giovanni Martinelli, Christoph Mamot, Emanuele Zucca

Blood Adv (2020) 4 (6): 1082–1092.

https://doi.org/10.1182/bloodadvances.2019001201

Published: 2020

Journal Articles

Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

Blood Adv (2020) 4 (2): 253–262.

https://doi.org/10.1182/bloodadvances.2019000875

Published: 2020

Journal Articles

Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity

Franziska Schramm, Udo zur Stadt, Martin Zimmermann, Norbert Jorch, Arnulf Pekrun, Arndt Borkhardt, Thomas Imschweiler, Holger Christiansen, Jörg Faber, Irene Schmid, Tobias Feuchtinger, Gerhard Beron, Monique L. den Boer, Rob Pieters, Martin A. Horstmann, Gritta E. Janka-Schaub, Gabriele Escherich

Blood Adv (2019) 3 (22): 3688–3699.

https://doi.org/10.1182/bloodadvances.2019000576

Published: 2019

Includes: Supplemental data

Journal Articles

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

Blood Adv (2019) 3 (13): 2013–2021.

https://doi.org/10.1182/bloodadvances.2019000251

Published: 2019

Journal Articles

Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children’s Oncology Group

Yousif Matloub, Karen R. Rabin, Lingyun Ji, Meenakshi Devidas, Johann Hitzler, Xinxin Xu, Bruce C. Bostrom, Linda C. Stork, Naomi Winick, Julie M. Gastier-Foster, Nyla A. Heerema, Eileen Stonerock, William L. Carroll, Stephen P. Hunger, Paul S. Gaynon

Blood Adv (2019) 3 (11): 1647–1656.

https://doi.org/10.1182/bloodadvances.2019032094

Published: 2019

Includes: Supplemental data

Journal Articles

MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma

Hanne Due, Anna Amanda Schönherz, Laura Ryø, Maria Nascimento Primo, Ditte Starberg Jespersen, Emil Aagaard Thomsen, Anne Stidholt Roug, Min Xiao, Xiaohong Tan, Yuyang Pang, Ken H. Young, Martin Bøgsted, Jacob Giehm Mikkelsen, Karen Dybkær

Blood Adv (2019) 3 (7): 1185–1196.

https://doi.org/10.1182/bloodadvances.2018029660

Published: 2019

Includes: Supplemental data

NARROW

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study

HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis

Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review

Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent–based analysis

Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines

Primary human herpesvirus 8–negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis

Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa

In childhood mature B-NHL with CNS disease, patients with blasts in cerebrospinal fluid are at higher risk of failure

Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma

Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant

Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma

Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification

Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model

Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children’s Oncology Group

MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only